Benchmark analyst Robert Wasserman raised the firm’s price target on Halozyme (HALO) to $68 from $55 and keeps a Buy rating on the shares on growing earnings momentum as well as anticipation of pending U.S. approval of Argenx’s (ARGX) subcutaneous Vyvgart for generalized Myasthenia Gravis, or gMG.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO: